Hospital
Public Health Trust of Miami Dade County Florida
Public Health Trust of Miami Dade County Florida was paid $8.02M by Medicaid between Jan 2018 and Dec 2024, across 210 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoPUBLIC HEALTH TRUST OF MIAMI DADE COUNTY FLORIDA
PALMETTO BAY, FL 33157
PALMETTO BAY, FL 33157
33aNPI1174601397assigned 11/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.02M
24GClaims440,906
24DCodes billed210
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#61 of 163
Median peer was paid$4.77M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KNIGHT, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,377 | $832K | |
| 2019 | 98,870 | $1.88M | |
| 2020 | 82,675 | $1.02M | |
| 2021 | 87,527 | $1.26M | |
| 2022 | 87,069 | $1.80M | |
| 2023 | 35,957 | $918K | |
| 2024incomplete | 13,431 | $307K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 17,422 | 14,802 | $1.11M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 12,880 | 11,394 | $924K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 12,662 | 10,107 | $773K |
| 80053 | Comprehensive metabolic panel | 5.9% | 28,646 | 19,184 | $475K |
| G0378 | Hospital observation service, per hour | 5.9% | 12,444 | 6,393 | $474K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 2,065 | 1,810 | $321K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.3% | 2,915 | 2,536 | $263K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 4,922 | 3,984 | $261K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.1% | 2,080 | 1,713 | $248K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.5% | 1,780 | 1,522 | $200K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 9,832 | 7,059 | $183K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 4,374 | 1,145 | $173K |
198 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 2,092 | $162K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 2,921 | $162K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 6,096 | $159K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 4,121 | $109K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 39,130 | $101K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 325 | $85K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,796 | $75K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,979 | $70K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,493 | $66K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,087 | $64K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 703 | $59K |
| 86850 | <1% | 2,750 | $57K | |
| 84703 | <1% | 8,044 | $52K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,429 | $51K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,436 | $50K |
| 97162 | <1% | 2,338 | $48K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 632 | $45K |
| 81001 | <1% | 13,195 | $41K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 638 | $39K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,886 | $37K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 426 | $37K |
| 84484 | <1% | 14,383 | $34K | |
| 86803 | <1% | 9,206 | $34K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 721 | $33K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,660 | $33K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,790 | $32K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,430 | $30K |
| 85610 | <1% | 10,965 | $30K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,548 | $29K |
| 85730 | <1% | 9,821 | $29K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,322 | $28K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 993 | $26K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 746 | $25K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,151 | $23K |
| 93017 | <1% | 363 | $22K | |
| 87631 | <1% | 789 | $22K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,348 | $22K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 166 | $21K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,281 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,786 | $17K |
| 84702 | <1% | 2,964 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,770 | $17K |
| 83690 | <1% | 4,708 | $17K | |
| 83050 | <1% | 1,826 | $16K | |
| 76801 | <1% | 1,279 | $14K | |
| 86900 | <1% | 2,869 | $14K | |
| 87186 | <1% | 1,506 | $14K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 168 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,632 | $13K |
| 86901 | <1% | 2,920 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,658 | $12K |
| 93971 | <1% | 317 | $12K | |
| 73630 | <1% | 680 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,481 | $11K |
| 72131 | <1% | 203 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,320 | $10K |
| 82803 | <1% | 1,938 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,219 | $10K |
| 82550 | <1% | 5,573 | $10K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,571 | $9K |
| 80061 | Lipid panel | <1% | 2,348 | $9K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,517 | $8K |
| 93970 | <1% | 380 | $8K | |
| 83880 | <1% | 2,672 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 105 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,174 | $8K |
| 92586 | <1% | 144 | $8K | |
| 82375 | <1% | 1,834 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,452 | $7K |
| 81003 | <1% | 1,222 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 469 | $7K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 153 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,625 | $6K |
| 87077 | <1% | 1,731 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 304 | $6K |
| 82330 | <1% | 1,718 | $6K | |
| 99205 | Prolong outpt/office vis | <1% | 93 | $6K |
| 73562 | <1% | 633 | $6K | |
| 86703 | <1% | 5,971 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,137 | $6K |
| 72100 | <1% | 674 | $5K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 163 | $5K |
| 87040 | <1% | 1,949 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,252 | $5K |
| 80320 | <1% | 2,540 | $5K | |
| 83735 | <1% | 3,293 | $5K | |
| 70498 | <1% | 15 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,648 | $4K |
| 73030 | <1% | 357 | $4K | |
| 82553 | <1% | 1,987 | $4K | |
| 87070 | <1% | 546 | $4K | |
| 82947 | <1% | 1,577 | $4K | |
| 97014 | <1% | 92 | $3K | |
| 97010 | <1% | 246 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 324 | $3K |
| 80051 | <1% | 1,547 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 149 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 314 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,542 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,670 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 768 | $3K |
| 82150 | <1% | 471 | $3K | |
| 73610 | <1% | 249 | $2K | |
| 83605 | <1% | 1,494 | $2K | |
| 80329 | <1% | 2,233 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,755 | $2K |
| 73130 | <1% | 213 | $2K | |
| 74174 | <1% | 15 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 493 | $2K |
| 87430 | <1% | 208 | $2K | |
| 87340 | <1% | 405 | $2K | |
| 86140 | <1% | 1,392 | $2K | |
| 85379 | <1% | 1,364 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 502 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,189 | $2K |
| 70486 | <1% | 56 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 577 | $2K |
| 81025 | <1% | 160 | $1K | |
| 92587 | <1% | 32 | $1K | |
| J3490 | Unclassified drugs | <1% | 1,287 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 423 | $1K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 175 | $1K |
| 97166 | <1% | 297 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $1K |
| 90715 | <1% | 724 | $1K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 270 | $1K |
| 87205 | <1% | 118 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 98 | $1K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 602 | $1K |
| 74240 | <1% | 48 | $1K | |
| 88304 | <1% | 438 | $1K | |
| 92558 | <1% | 122 | $1K | |
| 85652 | <1% | 600 | $1K | |
| 74018 | <1% | 144 | $843.16 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $803.37 |
| 82728 | <1% | 649 | $727.08 | |
| 84132 | <1% | 1,249 | $672.18 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 92 | $667.32 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 338 | $564.77 |
| 82435 | <1% | 1,074 | $560.53 | |
| 94760 | <1% | 52 | $544.09 | |
| 72040 | <1% | 30 | $530.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 64 | $529.10 |
| 97116 | <1% | 381 | $457.04 | |
| 80076 | <1% | 78 | $454.97 | |
| 85007 | <1% | 133 | $423.39 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 315 | $395.22 |
| 80164 | <1% | 19 | $348.26 | |
| 76770 | <1% | 31 | $304.13 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 360 | $277.88 |
| C1776 | Joint device (implantable) | <1% | 27 | $268.97 |
| 86702 | <1% | 14 | $267.40 | |
| 80069 | <1% | 30 | $262.01 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 38 | $249.92 |
| 92650 | <1% | 113 | $249.86 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 154 | $234.43 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $214.15 |
| 73502 | <1% | 18 | $184.35 | |
| 71250 | <1% | 32 | $175.91 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 16 | $171.77 |
| 83540 | <1% | 136 | $156.22 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 72 | $146.65 |
| 83615 | <1% | 566 | $139.01 | |
| 87075 | <1% | 26 | $126.45 | |
| 93880 | <1% | 33 | $122.89 | |
| 00731 | <1% | 42 | $110.32 | |
| 82009 | <1% | 43 | $102.32 | |
| 73110 | <1% | 29 | $99.65 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 100 | $96.53 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 249 | $94.32 |
| 84439 | <1% | 52 | $87.23 | |
| A9270 | Non-covered item or service | <1% | 250 | $80.52 |
| 85027 | <1% | 275 | $76.01 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 636 | $73.32 |
| 84100 | <1% | 332 | $71.95 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $55.16 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 16 | $47.64 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 105 | $41.37 |
| 85384 | <1% | 67 | $38.23 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $37.78 |
| 82607 | <1% | 96 | $35.31 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 31 | $31.44 |
| 83550 | <1% | 64 | $30.92 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 44 | $29.46 |
| 84145 | <1% | 97 | $21.29 | |
| 86701 | <1% | 14 | $17.06 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 114 | $13.79 |
| 82746 | <1% | 59 | $7.79 | |
| 82570 | <1% | 14 | $3.15 | |
| C9399 | Unclassified drugs or biologicals | 0% | 471 | $0.00 |
| 73560 | 0% | 37 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 171 | $0.00 |
| G9019 | Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project) | 0% | 37 | $0.00 |
| 88311 | 0% | 13 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 69 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 29 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 31 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKNIGHT, MARK (CHIEF FINANCIAL OFFICER)
Parent organizationPUBLIC HEALTH TRUST OF MIAMI DADE COUNTY
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.